Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Harry Raftopoulos

Showing results (11-20 of 20) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 20 results.
Cancer|August 17, 2005
Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and emesis over multiple cycles of moderately emetogenic chemotherapyJørn Herrstedt, Hyman B Muss, David G Warr, et al.
Lung Cancer (Amsterdam, Netherlands)|March 20, 2019
Pembrolizumab in combination with ipilimumab as second-line or later therapy for advanced non-small-cell lung cancer: KEYNOTE-021 cohorts D and HMatthew A Gubens, Lecia V Sequist, James P Stevenson, et al.
Lung Cancer (Amsterdam, Netherlands)|November 16, 2018
Pembrolizumab and platinum-based chemotherapy as first-line therapy for advanced non-small-cell lung cancer: Phase 1 cohorts from the KEYNOTE-021 studyShirish M Gadgeel, James P Stevenson, Corey J Langer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 20, 2005
Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapyDavid G Warr, Paul J Hesketh, Richard J Gralla, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 23, 2004
A phase II clinical and pharmacodynamic study of E7070 in patients with metastatic, recurrent, or refractory squamous cell carcinoma of the head and neck: modulation of retinoblastoma protein phosphorylation by a novel chloroindolyl sulfonamide cell cycle inhibitorRobert I Haddad, Lisa J Weinstein, Tad J Wieczorek, et al.
The Lancet. Oncology|October 18, 2016
Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 studyCorey J Langer, Shirish M Gadgeel, Hossein Borghaei, et al.
The New England Journal of Medicine|April 17, 2018
Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung CancerLeena Gandhi, Delvys Rodríguez-Abreu, Shirish Gadgeel, et al.
Cancer|February 11, 2004
A randomized controlled trial of darbepoetin alfa administered as a fixed or weight-based dose using a front-loading schedule in patients with anemia who have nonmyeloid malignanciesPaul J Hesketh, Francis Arena, Dhimant Patel, et al.
Journal for Immunotherapy of Cancer|July 6, 2019
Correction to: Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshopDavide Bedognetti, Michele Ceccarelli, Lorenzo Galluzzi, et al.
Journal for Immunotherapy of Cancer|May 23, 2019
Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshopDavide Bedognetti, Michele Ceccarelli, Lorenzo Galluzzi, et al.
Pageof 2

Showing results (11-20 of 20) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
Cancer|August 17, 2005
Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and emesis over multiple cycles of moderately emetogenic chemotherapyJørn Herrstedt, Hyman B Muss, David G Warr, et al.
Lung Cancer (Amsterdam, Netherlands)|March 20, 2019
Pembrolizumab in combination with ipilimumab as second-line or later therapy for advanced non-small-cell lung cancer: KEYNOTE-021 cohorts D and HMatthew A Gubens, Lecia V Sequist, James P Stevenson, et al.
Lung Cancer (Amsterdam, Netherlands)|November 16, 2018
Pembrolizumab and platinum-based chemotherapy as first-line therapy for advanced non-small-cell lung cancer: Phase 1 cohorts from the KEYNOTE-021 studyShirish M Gadgeel, James P Stevenson, Corey J Langer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 20, 2005
Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapyDavid G Warr, Paul J Hesketh, Richard J Gralla, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 23, 2004
A phase II clinical and pharmacodynamic study of E7070 in patients with metastatic, recurrent, or refractory squamous cell carcinoma of the head and neck: modulation of retinoblastoma protein phosphorylation by a novel chloroindolyl sulfonamide cell cycle inhibitorRobert I Haddad, Lisa J Weinstein, Tad J Wieczorek, et al.
The Lancet. Oncology|October 18, 2016
Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 studyCorey J Langer, Shirish M Gadgeel, Hossein Borghaei, et al.
The New England Journal of Medicine|April 17, 2018
Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung CancerLeena Gandhi, Delvys Rodríguez-Abreu, Shirish Gadgeel, et al.
Cancer|February 11, 2004
A randomized controlled trial of darbepoetin alfa administered as a fixed or weight-based dose using a front-loading schedule in patients with anemia who have nonmyeloid malignanciesPaul J Hesketh, Francis Arena, Dhimant Patel, et al.
Journal for Immunotherapy of Cancer|July 6, 2019
Correction to: Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshopDavide Bedognetti, Michele Ceccarelli, Lorenzo Galluzzi, et al.
Journal for Immunotherapy of Cancer|May 23, 2019
Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshopDavide Bedognetti, Michele Ceccarelli, Lorenzo Galluzzi, et al.
Pageof 2